在英国患有缺血性心脏病 (ALL- HEART) 的患者中,阿洛普林醇与常规治疗:多中心,前性,随机化,开放性,盲目的终点试验
在PubMed上查看摘要
概括
此摘要是机器生成的。在患有缺血性心脏病的患者中,阿洛普林醇治疗没有改善主要心血管结局. 在ALL- HEART试验中,阿洛普里诺和常规治疗组之间心脏病发作,中风或心血管死亡率没有显著差异.
科学领域
- 心脏病学
- 药理学
- 临床试验
背景情况
- 艾洛普林醇是一种具有潜在心血管益处的尿酸降低疗法.
- 在ALL- HEART研究中,研究了在患有缺血性心脏病的患者中Allopurinol的疗效.
研究的目的
- 确定艾洛普醇治疗是否改善主要的心血管结果.
- 评估阿洛普林醇对非致命的心肌梗塞,非致命中风或心血管死亡的影响.
主要方法
- 一个多中心,前性,随机的,开放的,盲目的终点试验.
- 5721名60岁以上的患有缺血性心脏病 (没有痛风病史) 的参与者被随机分组.
- 艾洛普林醇 (每天高达600毫克) 与通常治疗,平均随访时间为4. 8年.
主要成果
- 组间主要综合终点 (心肌梗塞,中风,心血管死亡) 没有显著差异 (HR1. 04, p=0. 65).
- 主要终点事件发生率为11%和11.3%的阿洛普里诺.
- 全因死亡率也没有显著差异 (HR1. 02, p=0. 77).
结论
- 在患有缺血性心脏病的患者中,阿洛普林醇治疗没有减少主要心血管事件.
- 这些发现不支持在该人群中使用阿洛普里诺来降低初级心血管风险.
相关概念视频
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

